HK1200816A1 - 布魯頓酪氨酸激酶抑制劑 - Google Patents

布魯頓酪氨酸激酶抑制劑

Info

Publication number
HK1200816A1
HK1200816A1 HK15101219.6A HK15101219A HK1200816A1 HK 1200816 A1 HK1200816 A1 HK 1200816A1 HK 15101219 A HK15101219 A HK 15101219A HK 1200816 A1 HK1200816 A1 HK 1200816A1
Authority
HK
Hong Kong
Prior art keywords
inhibitors
tyrosine kinase
brutons tyrosine
brutons
kinase
Prior art date
Application number
HK15101219.6A
Other languages
English (en)
Inventor
Christine Brotherton-Pleiss
Francisco Javier Lopez-Tapia
Yan Lou
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1200816A1 publication Critical patent/HK1200816A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK15101219.6A 2011-12-09 2015-02-04 布魯頓酪氨酸激酶抑制劑 HK1200816A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161568675P 2011-12-09 2011-12-09
PCT/EP2012/074581 WO2013083666A1 (en) 2011-12-09 2012-12-06 Inhibitors of bruton's tyrosine kinase

Publications (1)

Publication Number Publication Date
HK1200816A1 true HK1200816A1 (zh) 2015-08-14

Family

ID=47294913

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101219.6A HK1200816A1 (zh) 2011-12-09 2015-02-04 布魯頓酪氨酸激酶抑制劑

Country Status (11)

Country Link
US (1) US8742098B2 (zh)
EP (1) EP2788347A1 (zh)
JP (1) JP5832664B2 (zh)
KR (1) KR101673728B1 (zh)
CN (1) CN103998447A (zh)
BR (1) BR112014013582A2 (zh)
CA (1) CA2854603A1 (zh)
HK (1) HK1200816A1 (zh)
MX (1) MX2014006674A (zh)
RU (1) RU2014126750A (zh)
WO (1) WO2013083666A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2920162B1 (en) * 2012-11-16 2017-04-19 F. Hoffmann-La Roche AG Inhibitors of bruton's tyrosine kinase
DK3026050T3 (en) * 2013-07-26 2019-02-18 Carna Biosciences Inc NEW TRIAZINE DERIVATIVE
CA2922939A1 (en) * 2013-09-03 2015-03-12 Carna Biosciences, Inc. Novel 2,6-diaminopyrimidine derivative
CA2925177A1 (en) * 2013-09-20 2015-03-26 Carna Biosciences, Inc. Novel triazine derivative
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
WO2015151006A1 (en) 2014-03-29 2015-10-08 Lupin Limited Substituted purine compounds as btk inhibitors
WO2015157955A1 (en) 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
EP3137454A1 (en) 2014-04-28 2017-03-08 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
WO2015170266A1 (en) 2014-05-07 2015-11-12 Lupin Limited Substituted pyrimidine compounds as btk inhibitors
BR112022016432A2 (pt) 2020-02-20 2022-11-16 Hutchison Medipharma Ltd Compostos heterocíclicos de heteroarila e usos dos mesmos
MX2023003183A (es) 2020-09-21 2023-04-12 Hutchison Medipharma Ltd Compuestos heterociclicos de heteroarilo y usos de los mismos.
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR063946A1 (es) * 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
US8426441B2 (en) 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
ES2554615T3 (es) * 2008-05-06 2015-12-22 Gilead Connecticut, Inc. Amidas sustituidas, método de preparación y utilización como inhibidores de Btk
CN102066366B (zh) 2008-06-24 2014-04-16 霍夫曼-拉罗奇有限公司 新型取代的吡啶-2-酮和哒嗪-3-酮
CN102066370B (zh) * 2008-07-15 2014-05-14 霍夫曼-拉罗奇有限公司 苯基-咪唑并吡啶类和哒嗪类
ES2461494T3 (es) * 2008-07-18 2014-05-20 F. Hoffmann-La Roche Ag Nuevas fenilimidazopirazinas
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CA2852964A1 (en) * 2011-11-03 2013-05-10 F. Hoffmann-La Roche Ag Bicyclic piperazine compounds

Also Published As

Publication number Publication date
US20130150360A1 (en) 2013-06-13
US8742098B2 (en) 2014-06-03
JP2015500263A (ja) 2015-01-05
CA2854603A1 (en) 2013-06-13
KR20140105548A (ko) 2014-09-01
CN103998447A (zh) 2014-08-20
BR112014013582A8 (pt) 2017-06-13
JP5832664B2 (ja) 2015-12-16
WO2013083666A1 (en) 2013-06-13
BR112014013582A2 (pt) 2017-06-13
KR101673728B1 (ko) 2016-11-07
EP2788347A1 (en) 2014-10-15
RU2014126750A (ru) 2016-01-27
MX2014006674A (es) 2014-09-04

Similar Documents

Publication Publication Date Title
HK1194381A1 (zh) 酪氨酸激酶抑制劑
HK1197060A1 (zh) 酪氨酸激酶抑制劑
HK1212689A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
IL263262B (en) Atr kinase inhibitor compounds, preparations containing them, their uses and methods for their preparation
HK1186186A1 (zh) 酪氨酸蛋白激酶抑制劑
HK1211293A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
IL277951A (en) Pyrimidinyls are tyrosine kinase inhibitors
HK1208803A1 (zh) 布魯頓酪氨酸激酶抑制劑的晶形
HK1216887A1 (zh) 布魯頓酪氨酸激酶的抑制劑
PL2710005T3 (pl) Inhibitory kinazy tyrozynowej
HK1210779A1 (zh) 酪氨酸激酶抑制劑
HK1210461A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
HK1200816A1 (zh) 布魯頓酪氨酸激酶抑制劑
EP2710007A4 (en) Kinase Inhibitors
EP2632898A4 (en) HETEROCYCLIC TYROSINE KINASE HEMMER
IL228103A0 (en) Amino-quinolines as kinase inhibitors
HK1206624A1 (zh) 用於造血動員的布魯頓酪氨酸激酶抑制劑
EP2685992A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
EP2702064A4 (en) Kinase Inhibitors
HK1199873A1 (zh) 激酶抑制劑
HK1217695A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
HK1215855A1 (zh) 酪氨酸蛋白激酶抑制劑
HK1218416A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
HK1212975A1 (zh) 作為布魯頓氏酪氨酸激酶抑制劑的噻唑衍生物
HK1218394A1 (zh) 酪氨酸蛋白激酶抑制劑